URGN (STOCKS)
UroGen Pharma Ltd. Ordinary Shares
$20.620000
-0.950000 (-4.40%)
Prev close: $21.570000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Elizabeth Barrett
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $987.28M
- Employees
- 253
- P/E (TTM)
- -6.32
- P/B (TTM)
- -9.30
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
7
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.54 | $-0.51 | -0.0275 | -5.37% |
|
Sep 2025 (Q3)
|
$-0.69 | $-0.71 | +0.0164 | +2.32% |
|
Jun 2025 (Q2)
|
$-1.05 | $-0.85 | -0.1996 | -23.47% |
|
Mar 2025 (Q1)
|
$-0.92 | $-0.82 | -0.1040 | -12.75% |
Financial Statements
| Revenues | $109.79M |
| Benefits Costs and Expenses | $263.20M |
| Cost Of Revenue | $12.45M |
| Costs And Expenses | $263.20M |
| Gross Profit | $97.34M |
| Nonoperating Income/Loss | -$670.00K |
| Operating Expenses | $222.20M |
| Selling, General, and Administrative Expenses | $155.10M |
| Research and Development | $67.11M |
| Operating Income/Loss | -$124.86M |
| Income/Loss From Continuing Operations After Tax | -$153.49M |
| Income/Loss From Continuing Operations Before Tax | -$153.42M |
| Income Tax Expense/Benefit | $78.00K |
| Income Tax Expense/Benefit, Current | $78.00K |
| Net Income/Loss | -$153.49M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$153.49M |
| Net Income/Loss Available To Common Stockholders, Basic | -$153.49M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.19 |
| Basic Average Shares | 48,116,098 |
| Assets | $200.46M |
| Current Assets | $186.02M |
| Cash | $120.50M |
| Inventory | $16.46M |
| Other Current Assets | $49.06M |
| Noncurrent Assets | $14.43M |
| Fixed Assets | $637.00K |
| Other Non-current Assets | $13.79M |
| Liabilities | $305.93M |
| Current Liabilities | $46.42M |
| Accounts Payable | $12.14M |
| Wages | $13.52M |
| Other Current Liabilities | $20.77M |
| Noncurrent Liabilities | $259.51M |
| Long-term Debt | $125.00M |
| Other Non-current Liabilities | $134.51M |
| Equity | -$105.47M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$105.47M |
| Liabilities And Equity | $200.46M |
| Net Cash Flow From Operating Activities | -$162.44M |
| Net Cash Flow From Operating Activities, Continuing | -$162.44M |
| Net Cash Flow From Investing Activities | $61.56M |
| Net Cash Flow From Investing Activities, Continuing | $61.56M |
| Net Cash Flow From Financing Activities | $39.92M |
| Net Cash Flow From Financing Activities, Continuing | $39.92M |
| Net Cash Flow | -$60.97M |
| Net Cash Flow, Continuing | -$60.97M |
| Comprehensive Income/Loss | -$153.53M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$153.53M |
| Other Comprehensive Income/Loss | -$153.53M |
| Other Comprehensive Income/Loss Attributable To Parent | -$37.00K |